A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 2, 2008, Pages 125-135

  Baur, Martina ^a,b   Van Oosterom, Allan T ^c   Diéras, Véronique ^d   Tubiana Hulin, Michele ^e   Coombes, R Charles ^f   Hatschek, Thomas ^g   Murawsky, Michael ^h   Klink Alakl, May ^h   Hudec, Marcus ⁱ   Dittrich, Christian ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d INSTITUT CURIE   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h SANOFI   (France)

ⁱ UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anthracycline resistance; Docetaxel; Fluid retention; Metastatic breast cancer; Second line chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CETIRIZINE; DOCETAXEL; METHYLPREDNISOLONE; PACLITAXEL;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MOTONEURON; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 36849015318     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0259-0     Document Type: Article

References (44)

1. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernandez-Aramburo A, Sanchez-Rovira P, Amenedo M, Cosado A (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587-2593
2. Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla JP, Viens P, Faivre S, Chahine A, Spielman M, Bensmaiine A, Marty M, Mahjoubi M, Cvitkovic E (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18:562-573
3. Alexopoulos CG, Rigatos G, Efremidids AP, Papacharalambous A, Alexopoulos A, Vassilomanolakis M, Patila E for the Hellenic Cooperative Interhospital Group in Oncology (He-CIGO) (1999) A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Cancer Chemother Pharmacol 44:253-258
4. Ando M, Watanabe T, Nagata K, Narabayashi M, Adachi I, Katsunata N (2001) Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19:336-342
5. Bear HD, Anderson S, Brown A, Smith R, Mamounas E, Fisher B, Margolese R, Theroet H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
6. Behar A, Pujade-Lauraine E, Maurel A, Brun MD, Lagrue G, Feuilhade De Chauvin F, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid. Br J Clin Pharmacol 43:653-658
7. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87:1210-1215
8. Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, Schofield AC (2004) Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 6:R601-R607
9. Bruno R, Norton L (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65
10. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil MG, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, GonzalezMancha R, Richardsaon G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J for the 303 Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
11. Chang JC, Wooten EC, Tsimelzon A, Hilssenbeck Sg, Guteirrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177
12. CTC: National Cancer Institute (NCI): Common Toxicity Criteria (CTC); current version. http://www.ctep.info.nih.gov/reporting/ctc.html
13. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P (1996) A muticentric phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 74:650-656
14. Dittrich Ch, Jakesz R, Pirich K, Havelec L, Steger G, Schlappack O, Kolb R, Moser K (1987) Possibile adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer. J Cancer Res Clin Oncol 113:488-494
15. Eisenhauer EA, Trudeau M (1995) An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A (Suppl 4):S11-S13
16. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset J-L, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H (1996) A multicentre phase II study on the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171
17. Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104:121-129
18. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, Monden M, Noguchi S (2003) Prediction of response to docetaxel by quantitative analysis of class I and III ß-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9:2992-2997
19. Hopper-Borge E, Chen Z-S, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64:4927-4930
20. Hudis CA, Seidman AD, Crown JPA, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65
21. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431
22. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936-3945
23. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang S, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C The Breast Cancer International Research Group 001 Investigators (2005) Adjuvant docetaxel for node-positivebreast cancer. New Engl J Med 352:2302-2313
24. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
25. Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S (2005) Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Brest Cancer 12:11-15
26. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M for the 304 Study Group (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastin in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1424
27. Nabholtz J-M, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kenedy J, Azli N, Murawsky M, Riva A, Pouillart P for the TAX 306 Study Group (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
28. ®) in the UK. Ann Oncol 10:205-210
29. O'Shaughnessy J, Miles D, Vukelja S, Moiseywnko V, Ayoub J-P, Cervantes G, Fumoleau P, Jones St, Lui W-Y, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
30. Paridaens R, Van Aelst F, Georgoulias V, Samonigg H, Cocquyt V, Zielinski C, Hausmanninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N (2003) A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic brest cancer. Ann Oncol 14:433-440
31. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of decetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15:3149-3155
32. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82:529-534
33. Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracendione-resistant breast cancer. J Clin Oncol 13:2879-2885
34. Ravdin P, Valero V, Nabholtz J-M, Hortobagyi G, Oulid-Aissa D, Riva A, Houver C, Bellet R (1996) Efficacy of a 5-day corticosteroid premedication in ameliorating taxotere induced fluid retention. Proc ASCO 15; #124
35. Riva A, Fumoleau P, Roche H, Dieras V, Tubiana-Hulin M, Klink-Alakl M, Oulid-Aissa D, Van Glabbeke M, Lebecq A, Van Oosterom AT (1997) Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere®. Proc ASCO 16:188a, # 660
36. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Kerbrat P, Serin D, Lortholary A, de Ghislain C, Viens P, Bergerat JP, Geneve J, Martin AL, Asselain B (2004) Five years analysis of the PACS 01 trial: 6 cycles of FES 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Proc SABCS, #27
37. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, Kaye S (1993) Coping with toxicities of doceetaxel (Taxotere TM). Ann Oncol 4:610-611
38. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate-5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35a:1194-1201
39. ®) in patients with metastatic breast cancer. Ann Oncol 12:1393-1398
40. Trudeau ME (1999) Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Sem Oncol 26(Suppl 8):21-26
41. Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Sem Oncol 24(Suppl 13):S13-11-S13-18
42. Vici P, Belli F, Di Lauro L, Amodio A, Conti F, Foggi P, Gionfra T, Morelli MF, Botti C, Ferraironi A, Lopez M (2001) Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology 60:60-65
43. Wanders J, Schrijvers D, Bruntsch U, Gore M, Verweij J, Hanauske AR, Franklin H, Roenlvink M, Bayssas M, Kaye SB (1993) The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in taxotere studies. Proc ASCO, 12:# 94
44. Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Milllward MJ (1997) Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 39:557-560